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Abstract: 
Background & Aims: Alcohol consumption is a major cause of chronic liver 
disease, accounting for a large proportion of cirrhosis-related deaths worldwide.  Only a 
fraction of heavy alcohol drinkers develop advanced alcoholic liver disease (ALD), 
indicating that other factors likely contribute to the phenotypic heterogeneity.  Herein, 
we explored whether polymorphisms in the gene encoding Galectin-9 (LGALS9), 
previously shown to play key roles in mediating liver injury, were associated with 
development of ALD.  Methods: The study consisted of 554 individuals with at-risk 
alcohol consumption in the absence of other risk factors for chronic liver disease; 375 
patients had developed ALD.  All subjects were white Europeans who had consumed 
more than 80g of ethanol per day; 179 of these were controls with normal liver function 
and no clinical evidence of liver disease.  Results: Using data from the HapMap project, 
5 single nucleotide polymorphisms (SNPs) that tag all the common haplotypes were 
identified. Four of these SNPs (rs3751093, rs4239242, rs732222 and rs4794976) were 
associated with increased risk of developing ALD.  Moreover, using cells from healthy 
subjects, we found that the transcript and protein levels of Galectin-9 varied according 
to the carrier state of these alleles.  Multivariate analysis confirmed that rs4239242 and 
rs4794976 were associated with risk of ALD.  Conclusion: The sequence variations 
reported here may provide predictive information regarding the risk of developing ALD 
in at-risk individuals and identify novel therapeutic targets for this common disease.   
Keywords: Genetics; Cirrhosis; Human 
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Alcohol consumption is a major cause of chronic liver disease, accounting for a 
large proportion of cirrhosis-related deaths worldwide 1.  Alcoholic liver disease (ALD) 
comprises a broad spectrum of liver injury, ranging from simple steatosis to more 
severe forms, including alcoholic hepatitis, cirrhosis and hepatocellular carcinoma.  
Less than a third of heavy alcohol drinkers develop advanced ALD, indicating that other 
factors likely contribute to the phenotypic heterogeneity; these factors include gender, 
obesity, drinking patterns and duration, and non-sex-linked genetic factors 1, 2.  In this 
regard, genetic variation in the patatin-like phospholipase domain-containing 3 
(PNPLA3) gene has been associated with an increased risk of both alcohol-related 
cirrhosis and cancer3-6.  Candidate gene case-control studies have also found 
associations between ALD and single-nucleotide polymorphisms (SNPs) within genes 
coding for alcohol-metabolizing enzymes, antioxidant enzymes, and cytokines 7.  
Excessive tumor necrosis factor-α (TNF-α) production is characteristic of ALD.  Two 
TNF-α SNPs have been associated with the progression of ALD, although results in 
subsequent studies have been discrepant 7. 
 Galectins are evolutionarily conserved glycan-binding proteins with wide tissue 
distribution and critical functions in immune tolerance and inflammation 8.  Emerging 
data has implicated Galectin-9 (Gal-9), a tandem repeat-type galectin with two 
carbohydrate recognition domains, in hepatic immune homeostasis 9.  We had first 
reported that Gal-9 was upregulated by Kupffer cells in patients with chronic HCV 
infection, induced apoptosis of viral-specific CD8+ T cells, and that it increased 
production of pro-inflammatory cytokines (TNF-α, IL-1β) in liver-derived and peripheral 
mononuclear cells 10, implicating Gal-9 as a key mediator in pathways that lead to liver 
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injury.  Subsequent reports have ascribed central roles for Gal-9 in HBV-related 
hepatocellular carcinoma 11, autoimmune hepatitis 12, and ischemic-reperfusion injury in 
the liver 13.  Based on the broad functions of Gal-9 in a wide range of hepatic disorders, 
we hypothesized that functional genetic polymorphisms in the gene coding for Galectin-
9 (LGALS9) would be associated with development of ALD. 
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PATIENTS AND METHODS 
Study subjects: 
To be included in the study patients had to have been consuming more than 80 g 
ethanol/day for at least 10 years at the time of presentation, as detailed previously 14-16. 
After obtaining informed consent, blood (10 ml) was collected.  All patients were 
Caucasian and originated in the north-east of England as did their parents and 
grandparents. Heavy drinkers were recruited from two sources: referrals to the hospital 
liver unit with suspected ALD; and referrals to the Regional Alcohol Addiction Unit with 
alcohol dependency.  Patients who presented to the liver unit had their detailed lifetime 
alcohol history taken by a specific alcohol research nurse, and those who presented to 
the Alcohol Addiction Unit by a community psychiatric nurse trained in drug and alcohol 
addiction 14  The presence and severity of ALD was determined initially by standard liver 
blood tests. Patients with either alanine transaminase, alkaline phosphatase, or bilirubin 
more than twice the upper limit of normal on two occasions within a six month period 
were further investigated with ultrasonography.  If there was no evidence of biliary 
obstruction, liver biopsy was performed unless contraindicated by coagulopathy 
(prothrombin time more than three seconds prolonged).  The criteria for inclusion into 
the ALD group were either liver histology compatible with ALD or clinical evidence of 
hepatic decompensation.  For inclusion into the Alcoholic Control (Acon) group patients 
had to be actively drinking, have no clinical evidence of liver disease, and have either: 
normal liver blood tests on two occasions (not including an isolated rise in γ-glutamyl 
transferase) or, for those with abnormal liver blood tests, liver histology showing either 
normal liver or steatosis with no evidence of steatohepatitis or fibrosis.   Exclusion 
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criteria for this study were as follows: positivity to hepatitis B virus surface antigen or 
antibody to hepatitis C virus; other type of liver disease, including primary biliary 
cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, hemochromatosis (and 
other metabolic diseases), or alpha1-antitrypsin deficiency.   
 
In addition, 34 healthy subjects with no significant alcohol history were used to 
study the effect of PBMC stimulation on Gal-9 transcription in order to determine if 
SNPs were associated with differences in transcript and protein expression. 
SNP analysis: 
The selection of a candidate gene for an association study is usually based on 
the biological plausibility in chosen gene(s) that play a putative role in the pathogenesis 
of the disease of interest.  The LGALS9 gene is located on human chromosome 17 
(Chr17:25,958,174-25,976,586).  Using data from the HapMap project, 5 SNPs that tag 
all the common haplotypes (frequency > 0.01) were identified using Haploview. 
Genomic DNA was isolated from peripheral blood mononuclear cells (PBMC) from each 
of the study subjects. Genotyping for the selected LGALS9 polymorphisms was 
performed using allelic discrimination by LGC Genomics, Herts, UK.  In order to 
determine whether the allelic frequencies varied according to ethnicity, we used the 
1000 Genomes Project (http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes).  The 
average frequencies were determined from multiple groups: for whites (GBR- British in 
England and Scotland, FIN- Finnish in Finland, IBS – Iberian population in Spain, TSI- 
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Toscani in Italia, CEU – Utah residents with Northern and Western European ancestry); 
Hispanics (CLM- Columbians from Medellin, Columbia, MXL- Mexican Ancestry from 
Los Angeles, PUR- Puerto Ricans from Puerto Rico); for African Americans (ASW- 
Americans of African ancestry in SW USA). 
In vitro assays: 
PBMCs from control individuals who did not consume significant alcohol (n=34), 
at a concentration of 1 million/ml in 24 well plates, were cultured with IFN-γ (25ng/ml; 
R&D Systems), ethanol (EtOH, 25nM; Sigma) or a combination of both (IFN/EtOH) for 
24 hours.  Cells were harvested; RNA isolated using the RNeasy Mini kit (Qiagen), 
quantified using a Nanodrop microspectometer and 1 µg of RNA transcribed to cDNA 
using the Quantitect RT kit (Qiagen). Expression of LGALS9 was assessed by the Step 
One Plus Real time PCR system using the Fast SYBR Green Master Mix Protocol 
(Applied Biosystems). QuantiTect primer assays for use with Sybr Green were 
purchased from Qiagen/Superarray. For 8 selected individuals, cells were cultured as 
above and harvested for analysis of cell surface Gal-9 expression  by monocyte subsets 
(% positive compared to isotype control) using flow cytometry. Acquisition was 
performed using a BD FACSCanto II instrument (BD Biosciences, San Jose, CA) 
compensated with single fluorochromes and data was analyzed using Diva™ software 
(BD Biosciences).  Monocytes were distinguished by positive staining for CD14 and/or 
CD16 and high levels of HLA-DR, within a low forward-side scatter gate. Monocyte 
subsets were distinguished by the presence or absence of CD16 expression.  HLA-DR 
FITC clone LN3 was from eBioscience, CD14 APC-Cy7 clone MφP9 was from BD 
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Pharmingen.  Biolegend antibodies used were: CD16 pacific blue clone 3G8, Galectin-9 
PE clone 9M1-3, and IgG PE clone MOPC-21. 
 
Statistical analyses: 
PHASE software (v.2.1.1) was used for reconstructing haplotypes from genotype 
data using Bayesian statistics (see http://stephenslab.uchicago.edu/software.html)17 	 
Fisher’s exact test and Bonferroni-corrected threshold were used for significance (p < 
0.05).  Odds ratio and its 95% confidence interval were calculated for genotypes in ALD 
and control groups.  The Wilcoxon signed-rank test was used to compare fold increases 
of stimulated conditions with control conditions, and the non-parametric Mann-Whitney 
U-test was used to compare differences between groups. Calculations were performed 
using GraphPad Prism software.  
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RESULTS 
A total of 554 individuals with at-risk alcohol consumption in the absence of other 
risk factors for chronic liver disease comprised the current analyses.  All subjects were 
white Europeans who had consumed more than 80g of ethanol per day for 10 or more 
years. Of these, 375 patients had ALD, including 268 (71%) with cirrhosis and 74 
(19.7%) with alcoholic hepatitis.  As alcohol controls (Acon), 179 subjects with similar 
duration and degree of alcohol consumption but no clinical evidence of liver disease and 
normal liver function tests on at least two occasions (isolated increase in gamma-
glutamyltranspeptidase acceptable) were used.  This latter Acon group had a median 
age of 42 years, compared to 49 years for the ALD group and 73% were male, 
compared to 71% in the ALD group. 
 
Variants in LGALS9 associated with development of ALD in at-risk individuals 
Genomic DNA was isolated from this highly homogeneous group of 554 
individuals with similar exposures to alcohol but distinct phenotypic outcomes.  As 
described in the Methods, we tested five sequence variants in the human LGALS9 
gene.  Four of these SNPs were associated with the variable risk of developing ALD 
(Table 1). The frequencies of homozygous carrier state of the rs732222 [G] was over-
represented in the group not developing ALD. For the LGALS9 rs3751093, the 
proportion of homozygote G-allele carriers was significantly higher among at-risk 
individuals who were protected from developing alcohol-liver injury as compared to A-
allele carriers who were more prone to develop ALD.  We also found an association 
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between the rs4239242 [T] allele and protection from ALD; the presence of the C allele, 
as homozygote or heterozygote was associated with a 70% difference in risk of 
developing ALD (OR 1.72, CI: 1.21-2.46).  The frequencies of homozygous carrier state 
of the rs4794976 [T] was over-represented in the group not developing ALD.  In 
contrast, we did not find an association with the rs3763959 variant and risk of ALD.  
Haplotypes represent a combination of alleles at different markers along the same 
chromosome that are inherited as a unit 18, 19.  The distribution of haplotypes inferred for 
the variants are shown (Table 2); the H3 haplotype was protective against ALD (p = 
0.016) whereas the H4 haplotype was more frequent in patients with ALD (p = 0.024), 
although the numbers are relatively small. 
 
Functional genomics:  SNPs associated with variable production of Gal-9 
As these data are potentially consistent with loss-of-function and gain-of-function 
alleles, we next tested whether the natural occurrence of these variants was associated 
with expression of Gal-9 following stimulation with either IFN-γ (known to be a stimulant 
of Gal-9) 10, ethanol (25 nM) or the combination.  PBMC from thirty-four healthy subjects 
with no significant alcohol history were stimulated in culture for 24 hrs.  Interestingly, 
LGALS9 rs732222 GG homozygotes, rs3751093 GG homozygotes, and rs4239242 TT 
homozygotes demonstrated lower levels of Gal-9 transcription with ethanol stimulation 
(Figure 1), potentially consistent with genotype-associated protection from ALD.  Next, 
we selected normal subjects with “protective” SNPs (over represented in the Acon 
group) and those with “detrimental” variants (over-represented in the ALD group), as 
shown in Supplemental Table 1.  We stimulated cells with ethanol, IFN-γ (a known 
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stimulant of Gal-9 and an inducer of liver injury in rodent models of ALD20), either 
individually or in combination.  Using a FACS-based staining assay, we demonstrated 
that total monocytes as well as CD14posCD16neg classical monocytes 21 (the more 
frequent subset) produced more Gal-9 in the subjects with “detrimental” SNPs (Figure 
2).   There was also a significant increase in Gal-9 production in CD16pos non-classical 
monocytes (data not shown). Together, these data point to functional polymorphisms 
that result in differential expression of Gal-9 at the gene and protein levels. 
 
Minor allelic frequency of LGALS9 polymorphisms track with ethnic differences in 
ALD prevalence 
The incidence of ALD and ALD-associated mortality is known to vary according 
to ethnic origin within racial categories 22; Hispanic persons have a higher prevalence of 
chronic alcoholic liver disease than non-Hispanic whites and African-Americans (16.9 
vs. 11.1 vs. 9.9 per 100,000, respectively).  Moreover, data from a multicenter Veterans 
Affairs (VA) cooperative study found that among patients with acute alcoholic hepatitis, 
cirrhosis is more frequent in Hispanic (73%) than in non-Hispanic whites (52%) and 
African American (44%) patients 23.  Although perhaps confounded by behavioral 
patterns of alcohol consumption and differences in access to care, age-adjusted 
mortality rates from alcoholic cirrhosis for Hispanic men is two-fold higher than for non-
Hispanic white men 24, 25. 
As our study consisted of European Caucasians, we sought to examine how 
these SNPs might vary across ethnicities (Table 3).  Minor allelic frequency (MAF) 
refers to the frequency at which the least common allele occurs in a given population.  A 
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SNP with an allele (A) frequency of 0.30 (as for rs732222 among Hispanics; Table 3) 
means that 30% of a population has the A allele versus the most common (major) allele, 
in this case the G allele, which is found in 70% of the population.  Using data from the 
1000 Genomes Project, we found that the LGALS9 MAFs (associated with development 
of ALD) are highest among Hispanics. Thus, these results indicate that racial 
differences in the relative distribution of LGALS9 alleles may partially account for the 
observed ethnic associations with ALD.  Of note, the allelic frequencies of our cohort 
were similar to those reported previously for whites (rs732222:  0.26; rs3751093: 0.23 
and rs4239242: 0.38). 
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DISCUSSION 
This is the first study to examine the potential role of Gal-9 polymorphisms in 
ALD.  We selected Gal-9 as a candidate gene because of recent data implicating roles 
in a broad range of liver diseases 9-13.  Indeed, we first reported that Gal-9 was 
produced predominantly by Kupffer cells and induced secretion of pro-inflammatory 
cytokines 10.  Cytokines have been identified as central effector molecules in multiple 
steps mediating alcohol-related liver injury, including hepatocyte apoptosis, 
inflammatory cell recruitment, production of vasoactive molecules, and matrix 
deposition26.  In this large series of well-characterized patients with ALD with a control 
group of 179 subjects who consumed excessive alcohol but remained free of liver 
disease, we found associations between four LGALS9 variants and the relative risk of 
ALD.  Data from the UCSC Genome Browser site (hg19) supported a functional role for 
the majority of the variants associated with development of ALD identified in our study 
(http://genome.ucsc.edu/) 27.  After correction for multiple testing, two of the SNPs were 
associated with relative risk of developing ALD: rs4239242 (p = 0.017) and rs4794976 
(p = 0.032).    Moreover, in vitro, we demonstrated differential induction of Gal-9 at 
transcriptional and protein expression levels according to these variants.  Taken 
together, these data suggest a genetic basis for the variable expression of Gal-9 that, in 
turn, modulates the risk of developing ALD, although the precise mechanisms remain 
undefined. It would also be interesting to determine whether circulating levels of gal-9 in 
patients who drink excessive alcohol identifies those at risk of developing ALD. 
Nonetheless, theSNPs identified in the current study have potential utility in the 
identification and counseling of at-risk individuals.  In addition, we also recognize that 
14	
	
Gal-9 displays pleiotropic effects, including regulatory and potentially beneficial 
properties to limit immunopathology and/or fibrosis that warrant further study 9. 
 
There are several limitations of the current study worth noting.  Although the ALD 
and control groups were highly similar, including age, gender, race, consumption and 
duration of alcohol, not all the subjects had liver biopsies.  This could have 
underestimated the presence of mild liver disease in the control group, and hence the 
number of subjects actually protected from ALD.  The study group was highly 
homogenous (i.e., all European Caucasians and mostly males), potentially limiting the 
results’ applicability.  On the other hand, the MAFs reported by the 1000 Genomes 
Project lead us to speculate that these SNPs might correlate with the ethnic differences 
in ALD prevalence.  Analyses of more diverse cohorts are warranted, as well as patients 
with less severe forms of ALD (majority in our study had advanced ALD)  Finally, in 
order to determine whether other sequence variations in LGALS9 contribute to different 
risks of developing ALD, sequencing of the entire LGALS9 gene could be considered in 
an independent cohort.   
 
In summary, Gal-9, a tandem repeat-type galectin with two carbohydrate 
recognition domains, has been implicated in hepatic immune homeostasis and injury 9-
13. LGALS9 sequence variations reported here may provide predictive information 
regarding the risk of developing ALD in at-risk individuals and identify novel therapeutic 
targets for this common disease.   
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Table 1: Variants in the LGALS9 gene associated with development of alcoholic 
liver disease in at-risk individuals. 
SNP* Genotype ALD Acon Odds	Ratio p	Value 
 RS732222 GG 198	(52.8%) 112	(62.57%) 	 	 
 	 GA 159	(42.4%) 57	(31.84%) 
 
	 
 	 AA 18	(4.8%) 10	(5.59%) 1.49	(1.04-2.15) 0.035 
 RS3763959 GG 112	(30.03%) 52	(32.30%) 	 	 
 	 GA 192	(51.47%) 69	(42.86%) 
 
	 
 	 AA 69	(18.5%) 40	(24.84%) 0.69	(0.44-1.05) ns 
 RS3751093 GG 217	(56.51%) 123	(66.49%) 	 	 
 	 GA 155	(40.36%) 53	(28.65%) 
 
	 
 	 AA 12	(3.13%) 9	(4.86%) 1.52	(1.06-2.20) 0.028 
 RS4239242 TT 138	(36.51%) 92	(49.73%) 	 	 
 	 TC 194	(51.32%) 74	(40%) 
 
	 
 	 CC 46	(12.17%) 19	(10.27%)	 1.72	(1.21-2.46) 0.0034 
 RS4794976 TT 153	(41.13%) 97	(53.01%) 	 	 
 	 TG 196	(52.69%) 67	(36.61%) 
 
	 
 	 GG 23	(6.18%) 19	(10.38%) 1.66	(1.17-2.34) 0.0065 
 
       
       *Abbreviations:	SNP	Single	Nucleotide	Polymorphism;	ALD	Alcoholic	Liver	Disease;	Acon	
Alcoholic	control. 
 
Table 2: Haplotypes associated with development of alcoholic liver disease in at-
risk individuals. 
      Haplotypes 	 ALD Acon Odds	Ratio p	Value 
 H1 GAGTT 328	(0.41) 168	(0.44) 	 	 
 H2 AGACG 180	(0.22) 73	(0.44) 	 	 
 H3 GGGTT 133	(0.17) 86	(0.23) 0.68	(0.5-0.92) 0.016 
 H4 GGGCT 62	(0.08) 16	(0.04) 1.92	(1.09-3.35) 0.024 
 H5 GGGTG 28	(0.03) 13	(0.03) 	 	 
 H6 GAGCG 27	(0.03) 7	(0.02) 	 	 
 H7 AGGCG 17	(0.02) 13	(0.03) 	 	 
 	 Other 27	(0.03) 4	(0.01) 	 	 
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Table 3:  Minor allelic frequencies according to ethnicity (see methods and 
http://www.ncbi.nlm.nih.gov/variation/tools/1000genomes). 
 
rs number Hispanics Europeans-Americans African-Americans 
rs732222	[G] 0.30 0.23 0.196 
Rs3751093	[G] 0.267 0.196 0.123 
Rs4239242	[T} 0.4187 0.36 0.213 
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FIGURES 
 
 
Figure 1: LGALS9 SNPs are associated with variable gene expression. 
Thirty four normal control individuals were genotyped for SNPs in the LGALS9 gene. 
Peripheral blood mononuclear cells (PBMCs) from these individuals were cultured with 
IFN-γ (25ng/ml), ethanol (EtOH, 25nM) or a combination of both (IFN/EtOH) for 24 
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hours.  Cells were harvested, RNA isolated, cDNA transcribed and expression of 
LGALS9 was assayed using real-time PCR. For the SNPs shown the protective SNP 
(overrepresented in the control group; white bars) is compared to the other variants 
(black bars). Fold increase in LGALS9 expression is shown compared to media alone.  
Bars represent mean ± SEM and significance was tested using Student’s T test 
(*p<0.05). 
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Figure 2: LGALS9 SNPs are associated with variable production of galectin-9. 
We selected 4 individuals who had detrimental SNPs (overrepresented in alcoholic liver 
disease) and, 4 individuals who had protective (overrepresented in the alcoholic control 
group) SNPs in the four regions found to be significantly associated with the 
development of alcoholic liver disease (supplemental Table 1). Peripheral blood 
mononuclear cells (PBMCs) from these individuals were cultured with IFN-γ (25ng/ml), 
ethanol (EtOH, 25nM) or a combination of both (IFN/EtOH) for 24 hours.  Cells were 
harvested, and cell surface galectin-9 expression (% positive compared to isotype 
control) by classical (A), CD16+ monocytes and total monocytes (C) was determined 
using flow cytometry. Bars represent mean ± SEM and significance was tested using 
Student’s T test (*p<0.05). Representative flow plots of total monocytes treated with a 
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combination of IFN/EtOH are shown for one individual with detrimental and one with 
protective SNPs (C). 
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